4D Molecular Therapeutics vs Kymera Therapeutics
FDMT and KYMR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FDMT and KYMR compare
Kymera Therapeutics is the larger company, worth 12 times as much as 4D Molecular Therapeutics ($11.5B against $938M).
4D Molecular Therapeutics grew revenue faster over the last twelve months (278712% versus 134% for Kymera Therapeutics).
4D Molecular Therapeutics keeps more of each dollar of sales as profit, with a net margin of −195% compared with −342% at Kymera Therapeutics.
Kymera Therapeutics scores higher on the StockData Score (9 against 7 for 4D Molecular Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FDMT | KYMR |
|---|---|---|
| Size and price | ||
| Market cap | $938M | $11.5B |
| Share price | $12.99 | $134.84 |
| Change, 1 year | 27.7% | 120% |
| Change, 5 years | −43.7% | 119% |
| Beta (5Y) | 1.35 | 1.92 |
| Employees | 196 | 238 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.2× (better) | 113× |
| P/B | 2.3× (better) | 7.1× |
| FCF yield | – | −2.5% |
| Fair value | $12.76 | $37.80 |
| Margin of safety | −1.8% (better) | −257% |
| Growth | ||
| Revenue growth (TTM) | 278712% (better) | 134% |
| Revenue growth, 5Y average | 44.3% (better) | 2.9% |
| Profitability | ||
| Gross margin | – | 0.00% |
| Operating margin | −214% (better) | −396% |
| Net margin | −195% (better) | −342% |
| FCF margin | – | −283% |
| Return on equity | −43.3% | −27.3% (better) |
| Return on invested capital | −161% | −59.0% (better) |
| Financial health | ||
| Debt / equity | 0.05 (better) | 0.00 |
| Current ratio | 8.03 | 11.13 (better) |
| Altman Z-score | 3.87 | 44.09 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 80.5% | 114% |
| Held by insiders | 2.1% | 38.3% |
| Insider net buying, 12 months | −$5.3M (better) | −$301M |
| Short interest, % of float | 15.4% | 16.0% |
Go deeper
- FDMT stock overview
- FDMT income statement
- FDMT valuation and score
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.